MedTrace Logo

Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer

NCT07441369 · Status: ENROLLING_BY_INVITATION · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-04-27

No results posted yet for this study

Summary

This is a single-center, single-arm, open-label clinical study, to explore the efficacy and safety of abemaciclib combined with FOLFOX/FOLFIRI regimen in patients with advanced colorectal liver metastases cancer who failed standard two or three-line therapy.

Conditions

  • Liver Metastases From Colorectal Cancer (mCRC)

Interventions

DRUG

Abemaciclib

Abemaciclib was administered orally at 100-200mg twice daily for each 28-day cycle.

DRUG

Oxaliplatin

85mg/m², ivdrip, D1

DRUG

Calcium Folinate

400mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1

DRUG

5-Fluorouracil

400mg/m², iv, D1; and 2400mg/m², civ, 46-48h

DRUG

Irinotecan

180mg/m², ivdrip, D1

Sponsors & Collaborators

  • Shanghai Cancer Hospital, China

    collaborator OTHER

  • Fudan University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-01
Primary Completion
2027-04-30
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07441369 on ClinicalTrials.gov